Why is the Firebrick Pharma share price blazing 28% on Wednesday?

Firebrick shares are having a strong day on Wednesday…

| More on:
Concept image of a man in a suit with his chest on fire.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Firebrick Pharma Ltd (ASX: FRE) share price has been on form on Wednesday.

At one stage today, the clinical-stage pharmaceutical developer's shares were up 28% to 32 cents.

The Firebrick share price has since given back the majority of these gains but remains up 8% to 27 cents.

What's going on with the Firebrick share price today?

Investors have been bidding the Firebrick share price higher today despite there being no news out of the company.

However, it worth noting that prior to today the company's shares were trading 67% lower than their 52-week high.

So, with many beaten down ASX shares rebounding strongly today as investor sentiment improves, it isn't overly surprising to see Firebrick having a positive session.

Investors buying today appear optimistic that the company's Nasodine nasal spray still has a bright future despite being dealt a blow by the Therapeutic Goods Administration (TGA) earlier this month.

What happened to Nasodine?

Nasodine, a nasal spray intending to treat the common cold, was previously denied approval by the TGA.

The TGA then reaffirmed its stance earlier this month when the company received written advice from the regulator indicating that the section 60 request had resulted in confirmation of the original decision.

However, the company isn't accepting this and is now seeking to overturn this decision by applying for an independent review through the Administrative Appeals Tribunal (AAT).

Firebrick's executive chairman, Dr Peter Molloy, commented:

The s60 decision was always a possibility and we will now proceed to the next step in the appeal process. We strongly believe that the existing clinical data satisfactorily establishes the efficacy of Nasodine in the treatment of the common cold and that the AAT review should lead to an earlier approval of Nasodine.

We believe that because overall cold severity was not designated as the "primary" endpoint, the TGA has discounted the results.

No timeframe has been given for when a decision on the appeal will be made.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Concept image of a man in a suit with his chest on fire.
Record Highs

How long can the CBA share price keep this up?

Australia's biggest bank is running hot. Does it make any sense?

Read more »

Four people on the beach leap high into the air.
Broker Notes

4 ASX All Ords shares offering 10% to 30% annual growth: brokers

These ASX All Ords stocks have caught the eye of brokers this week.

Read more »

A young man wearing glasses writes down his stock picks in his living room.
Opinions

1 ASX stock I'm buying now that the US election is over

This ASX stock is appealing to me for a few different factors.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Rocket powering up and symbolising a rising share price.
Mergers & Acquisitions

Guess which ASX microcap stock just rocketed 67% on takeover news

Investors are sending the ASX microcap stock flying amid a takeover bid.

Read more »

Woman smiling with her hands behind her back on her couch, symbolising passive income.
Opinions

This ASX stock 10x my money. Here's why I haven't sold a single share

It looks stupidly expensive... so why have I held on this entire time?

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Here are 2 ASX shares that Morgans rates as buys

Let's see why the broker is feeling bullish on these stocks.

Read more »